June 21, 2017- Docetaxel-Based Triplet New Standard in Gastric Cancer
A new standard of treatment of care for resectable gastric or gastroesophageal (GEJ) adenocarcinoma is perioperative chemotherapy with docetaxel-based triplet. The MAGIC trial established perioperative epirubicin, cisplatin, and fluorouracil (ECF) as a standard of treatment for patients with operable esophagogastric cancer, but outcomes remain unsatisfactory. With the new method of treatment, docetaxel-based triplet FLOT, the median overall survival was higher and showed an increased rate of curative and prolonged progression-free survival when compared to ECF/ECX. With FLOT there was no increase in surgical morbidity and mortality, re-surgeries, and hospitalization time. Overall, FLOT improved outcome in patients with resectable gastric and GEJ cancer – making it the new standard of care in perioperative treatment of patients with such cancers.
View Full Article
Leave a Comment